PURPOSE OF REVIEW: In recent years, the N6-methyladenosine (m6A) modification of 
RNA has been shown to play an important role in the development of acute myeloid 
leukemia (AML) and the maintenance of leukemic stem cells (LSCs). In this review 
we summarise the recent findings in the field of epitranscriptomics related to 
m6A and its relevance in AML.
RECENT FINDINGS: Recent studies have focused on the role of m6A regulators in 
the development of AML and their potential as translational targets. The writer 
Methyltransferase Like 3 and its binding partner Methyltransferase Like 14, as 
well as the reader YTH domain-containing family protein 2, were shown to be 
vital for LSC survival, and their loss has detrimental effects on AML cells. 
Similar observations were made with the demethylases fat mass and 
obesity-associated protein and AlkB homologue 5 RNA demethylase. Of importance, 
loss of any of these genes has little to no effect on normal hemopoietic stem 
cells, suggesting therapeutic potential.
SUMMARY: The field of epitranscriptomics is still in its infancy and the 
importance of m6A and other RNA-modifications in AML will only come into sharper 
focus. The development of therapeutics targeting RNA-modifying enzymes may open 
up new avenues for treatment of such malignancies.